Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 7/20 | 0.71 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.71 |
| ▸ | PLG | P00747 | 4/20 | 0.71 |
| ▸ | KLK1 | P06870 | 4/20 | 0.71 |
| ▸ | F2 | P00734 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | HGFAC | Q04756 | 2/20 | 0.71 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.71 |
| ▸ | MLNR | O43193 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | C1R | P00736 | 1/20 | 0.71 |
| ▸ | F10 | P00742 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.71 |
| ▸ | HPN | P05981 | 1/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.71 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.71 |
| ▸ | C1S | P09871 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31380450 | 0.92 | F12 (0.76) | F12PRSS1PLGKLK1F2 | |
| SCHEMBL10922456 | 0.92 | FTO (0.74) | F12PRSS1PLGKLK1F2 | |
| Nafamostat SCHEMBL7051240 | 0.89 | PLAU (0.58) | F12PRSS1PLGKLK1F2 | |
| SCHEMBL7342376 | 0.88 | F12 (0.71) | F12PRSS1PLGKLK1F2 | |
| SCHEMBL7338848 | 0.88 | F12 (0.71) | F12PRSS1PLGKLK1F2 | |
| SCHEMBL20008705 | 0.88 | PLAU (0.61) | F12PRSS1PLGKLK1F2 | |
| Methane SCHEMBL11282601 | 0.86 | F2 (0.58) | F12PRSS1PLGKLK1F2 | |
| SCHEMBL7744358 | 0.85 | PARP10 (0.74) | F12PRSS1F2MAPTALDH1A1 | |
| SCHEMBL7342919 | 0.85 | KMT2A (0.64) | F12PRSS1PLGKLK1F2 | |
| SCHEMBL7340925 | 0.84 | F12 (0.66) | F12PRSS1PLGKLK1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57179146-A | — | — | None | — | — | JP | disclosed |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11197933-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11129825-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200101166-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2020-04-02 | — | — | US | disclosed |
| US-20190183884-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170100390-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2017-04-13 | — | — | US | disclosed |
| US-20140056964-A1 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-02-27 | — | — | US | disclosed |
| EP-0048433-B1 | NOVEL AMIDINE COMPOUNDS, PROCESS FOR PRODUCING SAME AND ANTI-COMPLEMENT AGENT COMPRISING THEM | TORII & CO., LTD. (JP) | 1986-05-28 | — | — | EP | disclosed |
| US-4532255-A | Amidine compounds and anticomplement agent comprising same | TORII & CO., LTD. (JP) | 1985-07-30 | — | — | US | disclosed |
| US-4454338-A | 6-AMIDINO-2-NATHTHYL-4-GUANIDINOBENZOATE | TORII & CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| JP-S57179146-A | AMIDINE COMPOUND | TORII YAKUHIN KK | 1982-11-04 | — | — | JP | disclosed |
| EP-0048433-A2 | Novel amidine compounds, process for producing same and anti-complement agent comprising them | TORII & CO., LTD. (JP) | 1982-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11197933-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | OPRM1, OPRK1, OPRL1 | F12 2691/4885PRSS1 1270/4885PLG 728/4885 |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | F12 3544/4885PRSS1 952/4885PLG 1237/4885 |
| US-20200101166-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRL1 | F12 2691/4885PRSS1 1270/4885PLG 728/4885 |
| US-20170100390-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | F12 3165/4885PRSS1 717/4885PLG 1740/4885 |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | F12 3165/4885PRSS1 717/4885PLG 1740/4885 |
| US-11129825-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | OPRK1, OPRM1, CYP3A5 | F12 3165/4885PRSS1 717/4885PLG 1740/4885 |
| US-20190183884-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | F12 3165/4885PRSS1 717/4885PLG 1740/4885 |
| US-20140056964-A1 | GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING | GZMB, PRF1, SERPINB1 | F12 655/4885PRSS1 267/4885PLG 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.